ישראל - עברית - Ministry of Health

amgen europe b.v. - panitumumab - תרכיז להכנת תמיסה לאינפוזיה - panitumumab 20 mg / 1 ml - panitumumab - in combination with chemotherapy for the treatment of unresectable, advanced or recurrent colorectal cancer (mcrc) with wild-type kras.monotherapy for the treatment of patients with metastatic colorectal carcinoma with wild-type kras after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

ישראל - עברית - Ministry of Health

merck serono ltd - cetuximab - תמיסה לאינפוזיה - cetuximab 5 mg/ml - cetuximab - cetuximab - erbitux® is indicated for the treatment of patients with epidermal growth factor receptor (egfr) - expressing, kras wild-type metastatic colorectal cancer• in combination with irinotecan-based chemotherapy• in first-line in combination with folfox• as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecanerbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck (scchn)• in combination with radiation therapy for locally advanced disease• in combination with platinum-based chemotherapy for recurrent and/or metastatic disease• as a single agent after failure of platinum-based chemotherapy for recurrent and/or metastatic disease

ישראל - עברית - Ministry of Health

j-c health care ltd - daratumumab - תרכיז להכנת תמיסה לאינפוזיה - daratumumab 20 mg / 1 ml - daratumumab

ישראל - עברית - Ministry of Health

j-c health care ltd - daratumumab - תמיסה להזרקה - daratumumab 120 mg / 1 ml - daratumumab

ישראל - עברית - Ministry of Health

novartis israel ltd - ofatumumab - תמיסה להזרקה - ofatumumab 50 mg/ml - ofatumumab

ישראל - עברית - Ministry of Health

eli lilly israel ltd - necitumumab - תרכיז להכנת תמיסה לאינפוזיה - necitumumab 16 mg / 1 ml - necitumumab

ישראל - עברית - Ministry of Health

gilead sciences israel ltd - sacituzumab govitecan - sacituzumab govitecan 200 mg

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - ofatumumab 20 mg/ml - concentrate for solution for infusion - ofatumumab - treatment of chronic lymphocytic leukaemia (cll) in patients who are refractory to fludarabine and alemtuzumab

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - ofatumumab 20 mg/ml - concentrate for solution for infusion - ofatumumab - treatment of chronic lymphocytic leukaemia (cll) in patients who are refractory to fludarabine and alemtuzumab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg/ml - rituximab - rituximab - mabthera is indicated for the following indications: * non-hodgkin’s lymphoma (nhl)mabthera is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, b-cell non-hodgkin’s lymphoma.mabthera is indicated for the treatment of previously untreated patients with low-grade or follicular lymphoma in combination with chemotherapy mabthera is indicated for the treatment of patients with cd20 positive diffuse large b-cell non-hodgkin's lymphoma in combination with chop chemotherapy. mabthera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. * chronic lymphocytic leukaemia (cll)mabthera in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including mabthera or patients refractory to previous mabthera plu